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Abstract: The right ventricle (RV) is integral to normal cardiac function, but receives little attention in the medical litera-
ture. The etiologic causes of acute RV failure often differ from those encountered in left ventricular dysfunction. Thus, 
RV failure frequently requires diagnostic procedures and management strategies that differ from those routinely used in 
the management of intrinsic left ventricular dysfunction. In this summary, the structure and function of the RV will be re-
viewed, concentrating on the pathophysiologic mechanisms behind the development of RV dysfunction. We will then fo-
cus on two distinct populations of patients who are at risk for acute RV failure: those with chronic pulmonary arterial hy-
pertension (PAH) and those with acute pulmonary embolism. In chronic PAH, we will examine clinical circumstances 
common to hospitalized patients that may provoke acute RV decompensation, as well as pharmacologic therapies that are 
unique to RV failure management in PAH. Individuals with acute RV failure in the setting of pulmonary embolism repre-
sent a group with particularly high mortality, and the specific diagnostic and management strategies that are important for 
improved survival will be discussed.  
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INTRODUCTION 
  The right ventricle (RV) differs structurally and function-
ally from its better studied neighbor– the left ventricle– often 
with a different etiology for its functional impairment. Thus, 
the diagnosis and management of acute RV failure often 
requires tactics that are distinctly different from those em-
ployed in patients with isolated intrinsic left ventricular dys-
function. In this article, we will overview the etiologies and 
pathophysiologic mechanisms behind the development of 
RV failure. We will also discuss the diagnosis and manage-
ment of acute RV failure in two important patient popula-
tions: hospitalized patients with pre-existing chronic pulmo-
nary hypertension and those with de novo RV dysfunction 
secondary to acute pulmonary embolism.  
PATHOPHYSIOLOGY OF ACUTE RIGHT VEN-
TRICULAR FAILURE 
  In 1936, Fineberg and Wiggers hypothesized that “circu-
latory failure following obstruction of the pulmonary circuit 
had no other cause than fatigue of the right ventricle [1].” 
Decades later, this postulation holds true. While the term 
pulmonary arterial hypertension (PAH) identifies a popula-
tion of patients with various degrees of pulmonary arteriopa-
thy and elevated vascular resistive indices, it is the function 
of the RV that determines much of the morbidity and mortal-
ity that occurs in PAH. Acute adverse disruptions in cardiac 
hemodynamics can provoke RV decompensation at a rate 
and threshold dependant on the structure and function of the 
underlying RV myocardium. Factors that affect RV after- 
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load, RV preload, and left ventricular (LV) function directly 
or indirectly impact the performance of the RV myocardium.  
Influence of Afterload on Right Ventricular Function 
  In normal individuals, the pulmonary circulation is a low 
resistance, high capacitance system capable of accommodat-
ing a three- to four-fold increase in RV stroke volume with-
out significantly raising pulmonary pressures. While the LV 
is mostly composed of fibers arranged in parallel creating a 
concentric-shaped ventricular cavity capable of withstanding 
highafterloads,theRV is crescent-shaped (Fig. 1a) with most 
of its fibers arranged in series [2]. The RV free wall is thin-
ner (<0.6 cm) and has a much lower volume-to-surface area 
ratio than the LV, allowing for increased RV compliance.  
  However, the crescent-shaped geometry of the RV also 
makes the chamber poorly tolerant of acute elevations in 
afterload. While chronic pulmonary hypertension stimulates 
adaptive changes in the RV myocardium that help maintain 
RV stroke volume, this does not occur in the acute setting. In 
normal individuals, the RV is unable to acutely generate a 
mean pressure >40 mmHg, and stroke volume decreases 
linearly as RV afterload increases (Fig. 2). Rapid elevations 
in afterload can cause acute RV dilation, damaging the con-
tractile sarcomere apparatus with resultant RV failure.  
Influence of Preload on RV Function 
  Right ventricular systolic function is also dependant on 
RV preload. Elevations in RV preload most commonly occur 
secondary to an elevation in intravascular volume or tricus-
pid regurgitation. With progressive RV dilation, the RV be-
gins to function on the descending portion of the Frank-Star-
ling curve, and a vicious cycle of “auto-aggravation” ensues 
[3]. As RV end-diastolic volumes and pressures increase, RV 
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(Fig. 1b). Elevated RV end-diastolic volumes also promote 
tricuspid annular dilatation, which worsens tricuspid valve 
insufficiency and decreases cardiac output.  
Fig. (2). Impact on right (RV) and left (LV) ventricular stoke vol-
umes with increased afterload. Acute increases in RV afterload lead 
to substantial decreases in RV stroke volume compared with that of 
the LV. PAP= pulmonary artery pressure. Reproduced with permis-
sion from Chin et al. [4].
Influence of Ventricular Interdependence on RV Func-
tion 
  Ventricular interdependence is the final factor that affects 
RV systolic function [3-5]. In order to generate a continuous, 
low pressure stroke volume during systole, the normal RV 
has three phases of systolic contraction: 1) contraction of the 
papillary muscles, 2) inward movement of the RV free wall  
towards the interventricular septum, and 3) contraction of the 
LV with subsequent medial displacement of the interven-
tricular septum towards the RV [3]. Perturbations in one ven-
tricle may directly impact the neighboring ventricle (Fig. 1b)
[3-4]. For example, increases in RV end-diastolic pressure 
and volume cause the interventricular septum to shift to-
wards the LV. Even in the setting of normal LV contractility, 
the reduced LV cavity size reduces stroke volume. Eleva-
tions in RV pressures also increase RV wall stress. This, in 
addition to increased myocardial oxygen demand in the set-
ting of RV hypertrophy, leads to a myocardial supply/de-
mand mismatch.  
  In converse, increases in LV volumes in the setting of LV 
systolic dysfunction shift the interventricular septum towards 
the right ventricle, increasing RV end-diastolic pressures. 
Thisexacerbatestricuspidregurgitationand wall stress, which 
initiates the “auto-aggravation” cycle. 
ACUTE RIGHT VENTRICULAR FAILURE IN 
CHRONIC PULMONARY HYPERTENSION 
  Acute RV failure in the setting of chronic pulmonary 
hypertension occurs as a consequence of complications that 
develop secondary to PAH disease management, from an 
acute worsening of previously stable pulmonary hyperten-
sion, and/or from the development of new cardiac abnormali-
ties that are either primary in etiology or secondary to preex-
isting PAH. In the following section, the etiologies precipi-
tating acute RV failure in hospitalized chronic PAH patients 
will be discussed, along with the strategies that should be 
employed to diagnose RV failure. Finally, we will review 
indications for vasopressor and inotrope support in RV fail-
ure and highlight vasodilator therapies unique to PAH man-
agement.  
Fig. (1). Short axis view of the right (RV) and left (LV) ventricles in a patient with normal (a) pulmonary pressures and in a patient with 
pulmonary hypertension (b). In normal individuals, note the crescent shape of the RV and the thin wall. In pulmonary hypertension, eleva-
tions in RV pressures increase myocardial wall stress. As the RV hypertrophies, myocardial oxygen demands also increase, culminating into 
a myocardial supply/demand mismatch (i). With increased RV filling pressure and volume, the septum is displaced towards the LV, reducing 
cardiac output (ii). Reproduced with permission from Chin et al. [4]. Acute Right Ventricular Failure in the Setting  Current Cardiology Reviews, 2008, Vol. 4, No. 1    51
Etiologies of Acute Right Ventricular Failure 
  While many patients with chronic PAH may appear clini-
cally compensated, some degree of underlying systolic 
and/or diastolic RV myocardial dysfunction exists. The 
tenuous nature of advanced chronic PAH allows RV failure 
to develop acutely with few insults. Successful management 
of acute RV failure is predicated upon rapid identification 
and management of its underlying potentiating causes.  
Myocardial Ischemia 
  Even in absence of significant obstructive atherosclerotic 
coronary disease, patients with chronic PAH are at risk for 
RV myocardial ischemia due imbalances in myocardial sup-
ply and demand that can develop with perturbations in RV 
preload and afterload, precipitating acute RV failure [6]. In 
normal individuals, the pressure-volume loop of the RV (Fig. 
3a) is more triangular than that of the LV (Fig. 3b), with 
short isovolumic contraction and relaxation periods, allow-
ing for sustained low pressure ejection [3, 7,8]. In this low 
pressure circuit, right coronary artery perfusion occurs dur-
ing both diastole and systole [9]. In right ventricles subjected 
to chronically elevated afterloads, the pressure-volume curve 
begins to look like that of the LV with a longer isovolumic 
contraction interval and cessation of systolic ejection at the 
onset of a prolonged isovolumic relaxation period [7,8]. In-
creased RV afterload and a prolonged isovolumic contraction 
time result in an increase in myocardial oxygen demand and 
Fig. (3). Pressure volume changes versus time during the contraction cycle (i) and the corresponding pressure-volume loop (ii) are shown for 
a normal patient (a) and a patient with elevated pulmonary afterload (b). In normals (a), the pressure-volume loop of the RV is more triangu-
lar than that of the LV with a poorly defined isovolumic contraction phase. In the presence of elevated RV afterload (b), the pressure-volume 
loop resembles that of the LV. Reproduced from Mebazza et al. [3] with permission. 52 Current Cardiology Reviews, 2008, Vol. 4, No. 1 Matthews and McLaughlin 
a reduction in right coronary artery systolic perfusion [9]. 
Elevated end-diastolic pressures in the setting of RV hyper-
trophy, intravascular volume overload, and tricuspid regurgi-
tation reduce diastolic right coronary perfusion and increase 
wall stress. Individuals with chronic PAH poorly tolerate 
coronary lesions and can even develop RV ischemia in the 
absence of significant obstructive coronary disease.  
  In chronic PAH patients with evidence of myocardial 
ischemia, measures should be undertaken to reduce myocar-
dial oxygen demands and improve coronary blood flow. Hy-
poxemia should be improved with supplemental oxygen. In 
patients with volume overload, diuresis should be attempted 
to reduce RV wall stress and hepatic/renal congestion. Right 
coronary blood flow can be augmented in individuals with-
out coronary obstruction with the use of the pure 1 agonist, 
phenylephrine, or with the combined 1 and 1 agonist, nore-
pinephrine. The improvement in coronary perfusion afforded 
by these agents must be balanced against the potential nega-
tive consequences of vasopressor-induced elevations in pul-
monary afterload and myocardial oxygen demands.  
  Chronic PAH patients with risk factors for coronary dis-
ease should rapidly undergo diagnostic evaluation with 
measures quickly instituted in those subjects with obstructive 
lesions to prevent myocardial necrosis and irreversible myo-
cardial failure. RV infarction secondary to a coronary steno-
sis typically occurs with a proximal occlusion of the right 
coronary artery but can also be seen with left anterior de-
scending (moderator branch artery) and circumflex artery 
occlusions. The EKG will most commonly show signs of an 
inferior or inferoposterior myocardial infarction with >1mm 
of ST elevation in leads II, III, and aVF with or without con-
comitant ST changes in lead V1. A right-sided EKG with ST 
elevation in V4R has a sensitivity of 88% and specificity of 
78% for diagnosing RV infarction [10]. Anti-platelet and 
antithrombin therapy with prompt percutaneous coronary 
revascularization is often necessary. Such patients are typi-
cally poor operative candidates. 
Sepsis 
  Patients with chronic PAH are at risk for the same infec-
tions encountered by the general public. However, due to 
their high frequency of hospital exposure and routine utiliza-
tion of indwelling central venous catheters for administration 
of vasoactive therapies, patients with chronic PAH are also 
at an increased risk for bacteremia (often with multidrug 
resistant organisms). In individuals with chronic PAH, cardi-
odepressive substances present in a septic milieu can precipi-
tate acute RV failure. With superimposed peripheral vaso-
dilatation, systemic pressures can drop below pulmonary 
pressures and Eisenmenger-type physiology can result with a 
potential for cyanosis in those patients with a patent foramen 
ovale. 
  Management of RV failure in chronic PAH patients with 
septicemia should be aimed at restoring systemic vascular 
resistance and treating the underlying pathogen(s). Intravas-
cular volume management in septic patients with hypoten-
sion and concomitant RV failure is difficult. LV preload is 
dependant upon pulmonary venous return, but this is often 
impaired in PAH due to RV systolic dysfunction. However, 
aggressive fluid resuscitation for blood pressure management 
during sepsis should be avoided in PAH patients. Instead, 
measures should be undertaken to improve systemic pres-
sures and end-organ perfusion with vasopressor and/or 
inotropic therapies. Dobutamine, dopamine, or norepineph-
rine can be initiated, but the tachycardia induced by these 
agents may be poorly tolerated. Phenylephrine should be 
employed cautiously, as the potent 1 agonist properties af-
fect both systemic and pulmonary vasculatures without pro-
viding inotrope support. Combination therapy may be re-
quired to achieve hemodynamic stability. 
  Once renal perfusion is improved, diuresis should be at-
tempted in those individuals who develop volume overload 
during resuscitation measures. Due to splanchnic congestion 
and diuretic resistance in hypertrophied renal tubules, high-
dose bolus diuretic therapy (with or without metolazone or a 
hydrodiuril primer) or continuous diuretic infusions may be 
necessary. A reduction in RV volumes will improve the 
Frank-Starling relationship and subsequently increase RV 
cardiac output.  
Pulmonary Embolism 
  Patients with chronic pulmonary hypertension are at risk 
for pulmonary embolism, both from in situ pulmonary arte-
rial clot formation and central venous catheter and deep ve-
nous sources. Recommendations on pulmonary embolism 
management will be provided later in this review. 
Arrhythmias 
  Patients with chronic PAH are at risk for atrial and ven-
tricular tachyarrhythmias, both of which are poorly tolerated 
and can lead to rapid RV failure and clinical decompensa-
tion. Tricuspid regurgitation is common in PAH, the severity 
of which increases as RV failure and annular dilatation pro-
gress. As the right atrium dilates to accommodate the regur-
gitant volume, fibrosis ensues. Areas of macro or micro-
reentry can subsequently develop and the nidus for atrial 
flutter and fibrillation, respectively, is created. Periods of 
increased atrial stretch (occurring with volume overload) and 
premature atrial contractions are enough to trigger reentry in 
those patients who are susceptible. Since many individuals 
with PAH are young and have fast AV nodal conduction 
velocities, they are capable of generating very rapid ventricu-
lar chronotropic responses. In the setting of PAH with a dys-
functional RV and preload dependant LV, a shortened dia-
stolic LV filling period can be catastrophic.  
  Therapy for atrial fibrillation and flutter should focus on 
rapid rhythm or rate control. Hemodynamically unstable 
patients should promptly undergo synchronized direct cur-
rent cardioversion (DCCV). In patients without significant 
hemodynamic embarrassment, rhythm control can be at-
tempted with amiodorone therapy. Beta-blockers and cal-
cium channel blockers should be used with extreme caution 
due to their negative inotropic properties. Digoxin loading 
can be attempted for rate control, but patients with renal dys-
function and those on epoprostenol therapy may require dose 
adjustments with close monitoring of serum digoxin levels.  
  Metabolic disturbances, including hypoxia and acidosis, 
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such disturbances become a source for atrial and ventricular 
arrhythmias that arise from myocardial automaticity. Atrial 
tachycardia and multifocal atrial tachycardia are two such 
supraventricular rhythms commonly encountered in RV fail-
ure. Both respond poorly to DCCV and therapy should be 
directed at correcting the underlying cause with rate control 
as discussed above. Automatic ventricular tachycardias are 
an ominous sign for patients with chronic PAH and RV fail-
ure. Unstable patients should undergo immediate defibrilla-
tion and efforts to correct metabolic insults (hyperkalemia, 
acidosis, hypoxia) should be undertaken. Recurrent arrhyth-
mias can be temporarily quiesced with antiarrhythmics such 
as amiodorone. 
Iatrogenic Causes of Right Ventricular Failure 
  Patients with severe chronic PAH poorly tolerate even 
small changes in hemodynamics. Right ventricular failure 
can result suddenly if vasoactive medications are acutely 
withdrawn or inappropriately initiated. Epoprostenol therapy 
has a half-life of about 2-5 minutes and severe, and poten-
tially fatal, rebound pulmonary hypertension has been known 
to occur with acute discontinuation of chronic epoprostenol 
infusion. This can also occur with abrupt discontinuation of 
high dose inhaled nitric oxide. Medications provided for 
other ailments can also have unfavorable hemodynamic ef-
fects on PAH patients. The negative inotropic properties of 
beta-blockers and some calcium channel blockers can pro-
voke RV decompensation. In the peri-procedure period, 
sedatives should be used with caution, beginning with small 
doses to avoid systemic hypotension. Vasodilators, like ni-
troprusside and milrinone, should be avoided in severe PAH 
due to the potential for hemodynamic compromise and Eis-
enmenger-type systemic flow reversals. Finally, in patients 
requiring mechanical ventilation, high plateau and high posi-
tive-end expiratory pressures (PEEP) increase ventricular 
end-diastolic pressures and can have negative effects on car-
diac output. 
Diagnosis of Right Ventricular Failure in Chronic Pul-
monary Hypertension 
  Identification of acute RV failure in chronic PAH re-
quires a compilation of data obtained from the vitals, the 
physical exam, laboratories, echocardiography, the EKG, 
and in some instances, Swan-Ganz catheterization. Cardiac 
physical exam findings common in RV failure include an RV 
heave, increased pulmonary component of the second heart 
sound, a right-sided S3, a tricuspid regurgitation murmur, 
jugularvenousdistention,and peripheral cyanosis and edema. 
Hepatomegly and ascites may also be present. Invasive blood 
pressure monitoring with blood gas measurement is often 
warranted to guide management of hypotension and hypoxia, 
respectively. Laboratories may reveal evidence of end-organ 
hypoperfusion with elevated creatinine and lactate and re-
duced serum sodium and bicarbonate. Brain natiuretic pep-
tide and troponins levels are frequently elevated due to myo-
cardial stretch and ischemia, respectively. Hepatic transa-
minase and bilirubin elevations indicate hepatic ischemia 
and/or congestion. Echocardiography and Swan-Ganz cathe-
terization can also be useful in diagnosing RV failure and 
will be discussed in detail later in the review. 
Pharmacologic Therapy Specific to Right Ventricular 
Failure in Chronic Pulmonary Arterial Hypertension: 
  Any of the above factors can cause an acute worsening of 
chronic PAH, leading to rapid clinical decompensation and 
RV failure. While identifying and managing the instigating 
factor is mandatory, therapy should also be aimed at improv-
ing RV failure directly. The judicious management of in-
travascular volume to reduce RV wall stress and the use of 
inotropes and pressors to improve cardiac contractility and 
coronary perfusion, respectively, has already been addressed. 
In addition, pharmacologic management with inhaled nitric 
oxide and epoprostenol can be employed. 
Inhaled Nitric Oxide 
  Endogenous nitric oxide was originally identified as “en-
dothelium derived relaxation factor” and functions a vasodi-
lator. Inhaled nitric oxide (iNO), a selective pulmonary 
vasodilator, traverses the endothelium in the precapillary 
pulmonary arteries and activates a heme moiety on guanate 
cyclase, inducing smooth muscle relaxation [11]. The half-
life of iNO is on the order of seconds and its rapid elimina-
tion by hemoglobin limits its vasodilatory properties to the 
pulmonary vasculature, making it ideal in the setting of sys-
temic hypotension due to RV failure from decompensated 
PAH.  
  Inhaled nitric oxide is not approved by the Food and 
Drug Administration (FDA) for the management of PAH. 
However, anecdotal data for the use of iNO exists and it is 
employed in some centers for PAH therapy. Inhaled nitric 
oxide can be administered via face mask or endotracheal 
tube, starting at 5 ppm and titrating to a maximum of 40 ppm 
to goal cardiac index. Methemoglobin levels should be moni-
tored every 6 hours and maintained at <5% hemoglobin to 
avoid methemoglobinemia. With reductions in pulmonary 
vasoconstriction, LV preload will improve and cardiac index 
will increase. Error should not be made in titrating iNO to 
pulmonary arterial pressures, as an increase in RV stroke 
volume with vasodilatation may result in increased pulmo-
nary artery pressures. Care should also be taken to avoid 
abrupt discontinuation of iNO, weaning in 5 ppm decrements 
until a dose of 5 ppm is reached.  
Epoprostenol 
 Prostaglandin  I2 (PGI2) is endogenously produced by 
endothelial cells and serves as a potent systemic and pulmo-
nary vasodilator with anti-proliferative and anti-thrombotic 
properties [12]. It functions in opposition to thromboxane A2
which induces vasoconstriction and platelet aggregation [13]. 
In the presence of hypoxemia, the response of smooth mus-
cle cells to PGI2 is reduced. In patients with PAH, throm-
boxane levels are increased relative to PGI2 and this imbal-
ance increases with progressive hypoxemia and RV dysfunc-
tion.  
  Given its vasoreactive properties, PGI2 has been syntheti-
cally reproduced in its salt form, epoprostenol, for manage-
ment of PAH. Epoprostenol’s systemic half-life is short (2-5 
minutes), limiting therapy to continuous intravenous infu-
sion. In addition to its vasodilatory properties, epoprostenol 
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RV function (possibly through increased inotropy), and to 
increase the clearance of the endogenous vasoconstrictor 
endothelin [3]. Studies have shown improved quality-of-life, 
NYHA functional class, and reduced mortality with epopros-
tenol therapy in chronic PAH [14]. While no studies to date 
have been performed in patients with acute RV failure, its 
use in the intensive care unit should not be prohibited. Many 
patients with chronic PAH are already on epoprostenol ther-
apy, and vasodilator infusion should be continued or even 
up-titrated. Abrupt discontinuation of intravenous epopros-
tenol should be avoided due to the possibility of rebound 
pulmonary hypertension.  
  In PAH patients naïve to epoprostenol, therapy should 
ideally be begun when the patient is hemodynamically stable 
(systolic blood pressures >80 mmHg). Dosing protocols vary 
from center to center. In the acute setting, a continuous infu-
sion is often started at 2 ng/kg/min and titrated by 0.5–1.0 
ng/kg/min every 30 minutes (maximum dose 12 ng/kg/min) 
until the desired cardiac index is achieved or side-effects 
(nausea, headache, diarrhea, myalgias) are encountered. Epo-
prostenol can be used in concert with iNO, and may assist in 
weaning iNO and vasopressor therapies in favor of long term 
therapy with epoprostenol. 
Endothelin Antagonists 
  Endothelin-1 is produced mostly by endothelial cells and 
has autocrine and paracrine properties, stimulating endothe-
lial smooth muscle cell vasoconstriction, platelet aggrega-
tion, extracellular matrix synthesis, and cytokine expression. 
In patients with chronic PAH, levels of endothelin-1 are ele-
vated and increase proportionally to the degree of pulmonary 
oxygen desaturation and pulmonary vascular hypertension 
[15,16]. Bosentan and ambrisentan are orally active endo-
thelin antagonists that inhibit the endothelin system by 
blocking endothelin receptors, including those in the pulmo-
nary vasculature. While placebo-controlled trials with endo-
thelin antagonists in chronic PAH have demonstrated im-
proved six minute walk distance, dyspnea, and cardiac index, 
there is currently no data for use of these agents in the setting 
of acute RV failure [17,18]. 
Atrial Septostomy 
  In selected chronic PAH patients with severe RV failure, 
atrial septostomy may allow for hemodynamic stabilization 
by reducing RV preload. The concept arose from observa-
tions that patients with chronic PAH who had patent foramen 
ovales (~ 25% of the population) lived longer than those who 
did not [19,20]. The procedure takes place in the interven-
tional cardiology suite and involves creating an interatrial 
connection by means of an atrial septal puncture with subse-
quent balloon dilation (Fig. 4). In patients with elevated 
right-sided pressures, blood flows down a pressure gradient 
to the left atrium, reducing right-sided wall stress and im-
proving RV cardiac output. While the shunted blood to the 
left atrium is deoxygenated, systemic oxygen transport may 
improve due to increased left ventricular stroke volumes. 
Atrial septostomy has been shown to improve clinical symp-
toms and hemodynamic parameters in hemodynamically 
stable chronic PAH patients with preserved RV function who 
are refractory to medical therapy [20]. However, studies 
suggest the procedure may be of less benefit, and may even 
be dangerous, in the setting of acute RV failure due to re-
duced systemic arterial oxygen saturations and elevations in 
left atrial pressure that may promote RV ischemia and pul-
monary edema, respectively [21].  
RIGHT VENTRICULAR FAILURE IN ACUTE PUL-
MONARY EMBOLISM 
  Acute pulmonary embolism (PE) is a disorder that affects 
at least one in every thousand individuals in the U.S., and as 
many as two-thirds of clinically significant PEs are undiag-
nosed pre-mortem due to its nonspecific clinical presentation 
Fig. (4). Atrial septostomy. An image of an atrial septal puncture is show above using transesophageal echocardiography during the proce-
dure. Using a specialized catheter and fluoroscopy, an atrial septal puncture is made in the region of the fossa ovalis and balloon dilation is 
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and a poor public awareness of the disorder [22-24]. Risk 
factors for PE include obesity, immobilization, cigarette use, 
cancer, surgery, trauma, pregnancy, oral contraceptives or 
hormone replacement therapies, and a prior history of PE or 
known hypercoagulable disorder. The clinical presentation of 
PE varies from an asymptomatic small pulmonary embolus 
with low mortality to a massive PE resulting in RV failure, 
shock, and/or death. The pathophysiology, diagnosis, man-
agement, and prognosis of acute RV failure in the setting of 
PE will be discussed below. 
Pathophysiology of Right Ventricular Failure in Acute 
Pulmonary Embolism 
  The hemodynamic response to an acute PE depends not 
only the size of the embolus and degree of pulmonary vascu-
lature obstruction, but also on the physiologic reaction to the 
vasoreactive substances released in response to the event and 
the cardiopulmonary status of the patient at baseline. In indi-
viduals without pre-existing cardiopulmonary disease, 25-
30% of the pulmonary vasculature must be occluded before 
pulmonary pressures begin to rise [25]. Likewise, the normal 
RV can generate up to a mean pulmonary artery pressure of 
40 mmHg acutely, requiring 50-75% of the pulmonary vas-
cular to be obstructed by clot before RV failure ensues 
[25,26]. Hypoxia induced by the emboli causes localized 
vasoconstriction. In addition, platelet and thrombin-rich clots 
stimulate the release of vasoactive mediators, such as sero-
tonin, thromboxane, and histamine, which lead to a further 
increase in pulmonary vascular resistance. While a patient 
may initially appear clinically stable, hypotension and shock 
can rapidly evolve as the RV begins to fail under the high 
afterload conditions. 
  While the mechanisms of acute RV failure in PE are 
similar to those seen in patients with acute RV failure in the 
setting of chronic PAH, patients without causes for preexist-
ing pulmonary hypertension lack the compensatory right 
ventricular hypertrophy meant to reduce wall stress in a high 
afterload state. The presence of a pre-existing coronary oc-
clusion or other cardiopulmonary comorbidities will also 
result in hemodynamic compromise at a lower level of pul-
monary arterial obstruction. 
Prognosis of Patients with Pulmonary Embolism and 
Right Ventricular Failure 
  The prognosis of PE correlates most directly with the 
degree of symptomatic hemodynamic compromise and as-
ymptomatic RV dysfunction. While cardiogenic shock oc-
curs in less than 5% of patients with PE, the mortality of 
patients with cardiogenic shock ranges from 25-40%, and is 
as high as 65-95% in patients requiring cardiopulmonary 
resuscitation [27-32]. The majority of patients who sustain 
massive PEs (defined as >50% occlusion of the pulmonary 
vasculature) do not have clinical cardiogenic shock and, 
therefore, have a much lower mortality than those patients 
with shock [28-33]. Anatomically massive PEs account for 
only 50% of the mortality in pulmonary embolism with the 
remaining fatalities occurring in patients with submassive or 
recurrent pulmonary emboli.  
   In patients who are clinically stable, it appears that RV 
function is an important prognostic indicator. RV dysfunc-
tion is diagnosed on transthoracic echocardiography in up to 
30-70% of normotensive PE patients [34-36]. The presence 
of RV dysfunction without hemodynamic compromise af-
fords a two-ten fold higher risk of short term death compared 
with normotensive patients without RV dysfunction [34-36]. 
The development of RV failure can be delayed by 12-48 
hours as the cycle of elevated afterload, RV dilation, tricus-
pid insufficiency, and RV hypokinesis unfold. Recurrent 
pulmonary emboli can also occur secondary to embolization 
of persistent deep venous clot, leading to rapid clinical de-
compensation. Thus, heightened suspicion for the presence 
of RV failure or RV dysfunction should be had for every 
patient admitted with acute pulmonary embolism, regardless 
of initial hemodynamic stability.  
Diagnosis of Acute Right Ventricular Failure in Pulmo-
nary Embolism 
  Rapid diagnosis of RV failure in patients with PE is im-
perative. Patients with fulminant RV failure in the setting of 
acute PE usually present dramatically with the typical symp-
toms of PE along with syncope, chest pain, cardiogenic 
shock, hypoxia, and/or cardiac arrest. The physical exam is 
similar to that encountered in chronic PAH patients with 
acute RV failure. The jugular venous pulse is often elevated 
with a prominent v wave. A parasternal RV heave may be 
palpable. On auscultation, a tricuspid murmur, increased S2, 
and in ~25% of patients, a right-sided S4 may be present 
[37]. In patients with normal LV function at baseline, the 
point of maximum impulse is hyperdynamic and a systolic 
flow murmur may be audible.  
EKG Abnormalities 
  There are several EKG abnormalities associated with PE, 
but none are highly specific or sensitive. In patients with RV 
failure, the EKG may show sinus tachycardia, signs of RV 
strain, repolarization abnormalities, or ischemia including a 
complete or incomplete right bundle branch block, a right 
ward axis (>90 degrees), an S1Q3T3 pattern, a Qr in lead 
V1, ST elevation in V1, or precordial T-wave inversions. 
However, approximately two-thirds of patients with massive 
or submassive PEs exhibit no such changes on EKG [38].
Two studies have demonstrated that T-wave inversions in the 
precordial leads correlate with both the severity of the PE 
and the presence of RV dysfunction [39,40]. Normalization 
of T-wave abnormalities implies a favorable outcome 
[39,40]. In a blinded study of 75 patients with PE, the pres-
ence of a Q wave 0.2 mV in lead V1 in patients with a QRS 
<120 ms had a specificity of 97% and a sensitivity of 31% 
for predicting moderate to severe RV dysfunction [41]. An 
increased mortality has also been found in acute PE patients 
presenting with atrial fibrillation, a low voltage QRS, and 
premature ventricular contractions, again likely reflecting the 
degree of RV failure and hemodynamic compromise [42]. 
While the EKG can not be used as a diagnostic tool for PE, it 
may suggest the presence of underlying RV dysfunction 
and/or reveal important alternative diagnoses (such as myo-
cardial infarction) in patients presenting with hypotension. 
Laboratory Abnormalities 
  It is not uncommon for patients with acute PE to present 
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ischemia in the setting of decreased coronary perfusion and 
increased myocardial demand. Cardiac troponins are ele-
vated in 7-32% of patients with PE and are strongly corre-
lated with the presence of RV dysfunction on echocardiogra-
phy [43-45]. Patients presenting with PE and positive tro-
ponins have an odds ratio for death of 15.2-21.0 and tropon-
ins remain a prognostic tool independent of echocardiogra-
phy, patient age, or degree of hypoxemia [43,46]. Likewise, 
plasma brain natriuretic peptide (BNP) levels have also been 
identified as a predictor of adverse outcome, likely reflecting 
the degree of myocardial stretch or pressure increase encoun-
tered by the afterloaded RV [47]. While elevations of BNP 
are correlated with increased mortality in acute PE, a low 
BNP level (50-90 pg/ml) does not guarantee an uncompli-
cated hospital course [48].
Transthoracic Echocardiography 
  Transthoracic echocardiography (TTE) is very useful in 
guiding the management of patients with suspected RV fail-
ure in the setting of both acute PE and chronic PAH. Echo-
cardiography can be used to elucidate the severity of pulmo-
nary hypertension and RV dysfunction, may visualize a PE 
“in transit,” and can identify alternative causes for hypoten-
sion (such as LV failure and pericardial effusion). In patients 
with acute PE, the presence of RV dysfunction affords an 
increased mortality and a 14% risk for recurrent pulmonary 
embolism [30, 49].  
  Abnormalities of the RV noted on TTE in the setting of 
acute massive PE and chronic PAH include RV hypokinesis, 
RV pressure and volume overload, and LV diastolic abnor-
malities incurred from a failing RV. A pulmonary vascular 
obstruction of >30% has been shown to correlate with the 
presence of RV dysfunction on echo [50]. In a prospective 
study of 209 patients with documented PE, TTE was found 
to have a 100% negative predictive value for predicting PE 
related death on the basis of RV dysfunction, but a positive 
predictive value of only 5% [36]. Thus, transthoracic echo is 
useful for early detection of RV dysfunction in normotensive 
patients who are at higher risk for hemodynamic decompen-
sation, but with a low specificity (61%).  
  Signs of RV dysfunction with dilation on TTE include: 1) 
a ratio of RV to LV end diastolic diameter >1 in the apical 
four chamber view, or 2) an RV end diastolic diameter >30 
mm and/or loss of inspiratory collapse of the inferior vena 
cava (IVC). In contrast to the global hypokinesis seen in 
PAH patients with RV failure, PE patients may exhibit spar-
ing of the RV apex with hypokinesis of the RV free wall and 
base –a finding termed the “McConnell sign.” The McCon-
nell sign has been shown in one study to have a specificity of 
94% and sensitivity of 77% for diagnosing PE [51].
  When the RV becomes pressure overloaded, the interven-
tricularseptumdeviates towardthe LV, creating a “D” shaped 
septum on parasternal short axis TTE images. The displaced 
septum impedes diastolic mitral inflow, increasing the de-
mand on atrial systole for LV diastolic filling. This results in 
a diastolic filling pattern on Doppler interrogation of the 
transmitral inflow called “E to A reversal,” with an increased 
A (atrial systole) wave compared to the reduced E (passive 
atrial filling) wave.  
  An estimation of pulmonary artery systolic pressure can 
be obtained from the regurgitant jet of the tricuspid valve. 
The pulmonary artery systolic pressure (PAP) is estimated 
from the right ventricular systolic pressure (RVSP), accord-
ing to the formula: PAP = RVSP + estimated right atrial 
pressure. The RVSP is obtained from the velocity (v) of tri-
cuspid regurgitant jet, such that RVSP = 4v
2. Right atrial 
pressure is estimated from atrial size or IVC engorgement. 
While easy to obtain, the RVSP can be greatly underesti-
mated or unobtainable in the setting of an inadequate Dop-
pler signal (due to obesity, pulmonary hyperinflation, me-
chanical ventilation, or angulation of the heart) or with poor 
alignment of the transducer probe with the tricuspid jet. In 
patients with pulmonary embolism, absence of any tricuspid 
regurgitation on a quality echo makes the presence of severe 
pulmonary hypertension unlikely, while a tricuspid jet veloc-
ity > 3.7 m/s or an RV wall thickness > 5 mm suggests the 
presence of preexisting cardiopulmonary disease, such as 
chronic PAH [52].  
  Rarely, TTE or transesophageal echocardiography (TEE) 
can be diagnostic of PE, visualizing the presence of clot, 
termed a PE “in transit,” in the IVC, RV, or pulmonary ar-
tery (Fig. 5). TEE can be employed at the bedside in patients 
too unstable to undergo radiologic imaging. In experienced 
centers, the sensitivity of TEE for detecting central PE is 80-
97% with a specificity of 84-100% [53,54]. Beyond the 
proximal pulmonary arteries, however, the sensitivity of TEE 
for identifying emboli drops markedly. While TTE and TEE 
can not rule out the diagnosis of PE, the presence of emboli 
“in transit” is a clear indication for therapy.  
Swan-Ganz Catheterization 
  Pulmonary artery Swan-Ganz catheterization can be use-
ful in selected patients with chronic PAH or PE and hypoten-
sion of unclear etiology, allowing one to differentiate RV 
failure from other causes of hypotension, including sepsis 
and hypovolemia. Echocardiography is useful prior to cathe-
terization to screen for RV clot that may complicate catheter 
placement.  
  The results of the Swan must be taken in context of pre-
existing cardiopulmonary disease. In patients with pulmo-
nary emboli who do not have pre-existing cardiopulmonary 
disease, an elevation in the right atrial (RA) pressure sug-
gests the presence of a high pulmonary vascular clot burden. 
When the RA pressure is 10 mmHg in a previously normal 
RV, there is likely 50% obstruction to the pulmonary vas-
culature [25]. While patients with small PEs typically have 
normal or supranormal cardiac output with normal or mildly 
elevated RA pressures, patients with chronic PAH and other 
causes for cardiopulmonary dysfunction will have a reduc-
tion in cardiac output and mixed venous oxygen saturation 
with a greater increase in RA pressure. As RV failure pro-
gresses, RA pressures elevate while pulmonary pressures 
often decline to near normal values due to reductions in RV 
stroke volume. The presence of a reduced cardiac output 
with a normal RA pressure suggests the presence of alterna-
tive etiologies for hypotension. 
  In chronic PAH patients with PE, RA pressures on cathe-
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lar obstruction. In complicated hypotensive patients with PE 
and an unclear preexisting cardiopulmonary disease history, 
it has been suggested that a mean pulmonary artery pressure 
to percent of angiographic obstruction ratio 1.0 represents a 
vascular hypertensive response in a patient who has a con-
comitant limitation in cardiac reserve [26]. 
Management of Right Ventricular Failure in Acute Pul-
monary Embolism 
  Management of patients with acute PE is dictated by the 
presence or absence of hemodynamic compromise. Patients 
presenting with PE in cardiogenic shock should immediately 
receive vasopressor support, anticoagulation, and then be 
considered for thrombolysis and/or embolectomy where 
available. While heparin reduces the morbidity and mortality 
from recurrent PEs, it does not affect the clot(s) causing the 
initial hemodynamic insult. Thrombolytic agents accelerate 
clot lysis by converting plasminogen to its active form, 
plasmin, dissolving intrapulmonary clot and clot that is at 
risk for subsequent embolization from the deep veins. At 
present, there are three agents (streptokinase, urokinase, tis-
sue plaminogen activator) approved by the FDA for throm-
bolysis of pulmonary emboli. All are administered intrave-
nously or angiographically for direct clot lysis in patients 
without contraindications. 
  While no large individual trial has demonstrated a statis-
tically significant mortality benefit from lytic therapy com-
pared with heparinization alone in patients with PE, lysis 
does lead to a more rapid reduction in angiographic clot bur-
den and pulmonary hypertension, restores RV function, and 
reduces the risk of recurrent pulmonary emboli [55]. How-
ever, lytic therapy must be weighed against the 9-22% risk of 
major bleeding, including a 1-5% risk of intracranial hemor-
rhage [29,55-58].  
  Metaanalyses of lytic therapy trials have shown that the 
majority of benefit from thrombolytic therapy is limited to 
PE patients with hemodynamic instability [35]. While nor-
motensive patients with evidence of RV dysfunction have 
increased mortality and thrombolytic therapy has been shown 
to improve RV dysfunction, definitive data demonstrating a 
significant morbidity and/or mortality benefit from lytic 
therapy in this population is lacking. Several studies have 
examined the efficacy of lytic therapy in normotensive pa-
tients with RV dysfunction and PE, but they lack uniform 
tools (TTE vs. EKG) and uniform terminology for defining 
RV dysfunction and/or fail to state how outcome criteria for 
PE related mortality was assessed [35], fail to confirm the 
diagnosis of PE [34], or have potential patient selection bi-
ases [58]. Despite the high specificity of TTE, the positive 
predictive value of the modality in predicting in hospital 
mortality is low (4-5%), potentially subjecting an unneces-
sarily large number of patients to lytic therapy [35]. Further, 
studies that limit data to normotensive patients with PE-
related RV dysfunction reveal lower short-term mortality 
differences (4-5%) than trials examining mortality differ-
ences (4-14%) in all PE patients with RV dysfunction [35-
36]. Thus, further studies are needed to determine which 
hemodynamically stable patients will benefit from lytic ther-
apy in the setting of RV dysfunction.  
  Unstable patients with pulmonary emboli who have 
failed maximal medical management with pressor resistant 
hypotension or cardiac arrest, or who have contraindications 
to thrombolytic therapy can be considered for percutaneous 
or surgical embolectomy. Catheter based embolectomies 
include clot aspiration, clot fragmentation, and rheolytic 
thrombectomy. The percutaneous techniques, however, are 
limited by the size of clot that can be removed through a 
small catheter lumen. Surgical embolectomy is not widely 
available but offers the ability to extract larger clots while 
providing cardiopulmonary bypass support. The current data 
available on embolectomy is from case reports or trials with 
small numbers of patients. But, mortality varies from 16-
46%, with the higher mortality found in older studies and in 
Fig. (5). Pulmonary embolism in transit. This short axis tranthoracic echocardiogram image shows an embolism (*asterix) passing through 
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studies that included patients with cardiac arrest [52, 59,60]. 
Antecedent lytic therapy has not been cited as a contraindica-
tion to surgical embolectomy, but an increase in complica-
tions should be anticipated.  
  Finally, in patients presenting with RV failure, a differen-
tiation between acute and chronic pulmonary embolism is 
required as management strategies, follow-up, and prognosis 
differ. Patients with acute PE should have close follow-up 
after discharge to ensure that chronic thromboembolic pul-
monary hypertension does not develop. Treated patients with 
dyspnea that persists in the outpatient setting should provoke 
concern for the development of chronic pulmonary embolic 
hypertension, and radiologic imaging (contrasted computed 
tomography or ventilation perfusion scanning) should be 
employed. These patients should be referred to a PAH spe-
cialist for consideration of thromboendarterectomy, vasodila-
tor therapy, or lung transplantation as appropriate. 
CONCLUSION 
  Acute RV failure in the setting of chronic pulmonary 
hypertension and acute PE portend a high morbidity and 
mortality. Management strategies should focus on identify-
ing precipitating factors, restoring oxygenation and hemody-
namic stability, and employing pharmacologic therapies 
and/or procedures shown to improve outcome. Consultation 
with a pulmonary hypertension specialist should be strongly 
considered to assist with medical management and to guide 
referral for surgical intervention. 
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